Issue

Vol. 33 No. 4 (2021): Vol 33 Issue 4

Copyright (c) 2021 AJC

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Novel RP-HPLC-PDA Approach for Efficient Simultaneous Quantification of Imipenem, Cilastatin and Relebactum in Bulk Drug and Injection Dose Forms

https://doi.org/10.14233/ajchem.2021.23111
Krishnaphanisri Ponnekanti
Department of Pharmacy, GITAM Institute of Pharmacy, GITAM Deemed to be University, Visakhapatnam-530045, India
K. Sunitha
Department of Pharmacy, GITAM Institute of Pharmacy, GITAM Deemed to be University, Visakhapatnam-530045, India

Corresponding Author(s) : Krishnaphanisri Ponnekanti

krishnaphanisri@gmail.com

Asian Journal of Chemistry, Vol. 33 No. 4 (2021): Vol 33 Issue 4

Abstract

In this investigation, a highly reliable, precise, stability indicating, specific and selective RP-HPLC approach with photodiode array detection (RP-HPLC-PDA) was established to determine simultaneously imipenem, cilastatin and relebactum in bulk drug and injection dose forms. Chromatographic separation of imipenem, cilastatin and relebactum was achieved via using C18 XTerra column and a mobile phase poised of acetonitrile and 0.1 M dipotassium hydrogen phosphate buffer (4.5 pH, set with 0.1% orthophosphoric acid) at 45:55 (v/v) ratio with a flow stream of 1 mL/min. The photodiode array detector was fixed at wavelength 245 nm and quantifications of imipenem, cilastatin and relebactum were based on assessing their peak response areas. Good linearity was detected in target range concentrations of 250-750 μg/mL (imipenem and cilastatin) and 125-375 μg/mL (relebactum). The precision (standard variation percentage) was between 0.141% and 0.257%. Accuracy (%assay nominal) determined was between 99.144% and 99.638%. The validated RP-HPLC approach was applied to Recarbio injection dose evaluating imipenem, cilastatin and relebactum content with no interference encountered from the injection dose inactive ingredients. Imipenem, cilastatin and relebactum were subjected to forced conditions like 30% peroxide, 0.1 N NaOH, sunlight, 0.1 N HCl and 60 ºC. Imipenem, cilastatin and relebactum were effectively separated, quantified and resolved from the degradants generated in forced conditions.

Keywords

Imipenem Cilastatin Relebactum Degradation study RP-HPLC Validation
Ponnekanti, K., & Sunitha, K. (2021). Novel RP-HPLC-PDA Approach for Efficient Simultaneous Quantification of Imipenem, Cilastatin and Relebactum in Bulk Drug and Injection Dose Forms. Asian Journal of Chemistry, 33(4), 897–902. https://doi.org/10.14233/ajchem.2021.23111
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. K.M. Papp-Wallace, A. Endimiani, M.A. Taracila and R.A. Bonomo, Antimicrob. Agents Chemother., 55, 4943 (2011); https://doi.org/10.1128/AAC.00296-11
  2. M.I. El-Gamal, I. Brahim, N. Hisham, R. Aladdin, H. Mohammed and A. Bahaaeldin, Eur. J. Med. Chem., 131, 185 (2017); https://doi.org/10.1016/j.ejmech.2017.03.022
  3. A.C. Rodloff, E.J.C. Goldstein and A. Torres, J. Antimicrob. Chemother., 58, 916 (2006); https://doi.org/10.1093/jac/dkl354
  4. H.F. Chambers, J. Turner, G.F. Schecter, M. Kawamura and P.C. Hopewell, Antimicrob. Agents Chemother., 49, 2816 (2005); https://doi.org/10.1128/AAC.49.7.2816-2821.2005
  5. J.A. Klastersky, Int. J. Antimicrob. Agents, 21, 393 (2003); https://doi.org/10.1016/S0924-8579(03)00002-5
  6. S. Keynan, N.M. Hooper, A. Felici, G. Amicosante and A.J. Turner, Antimicrob. Agents Chemother., 39, 1629 (1995); https://doi.org/10.1128/AAC.39.7.1629
  7. X. Huo, Q. Meng, C. Wang, Y. Zhu, Z. Liu, X. Ma, X. Ma, J. Peng, H. Sun and K. Liu, Acta Pharm. Sin. B, 9, 986 (2019); https://doi.org/10.1016/j.apsb.2019.02.005
  8. M. Shayan and S. Elyasi, Expert Opin. Drug Saf., 19, 999 (2020); https://doi.org/10.1080/14740338.2020.1796967
  9. K.M. Papp-Wallace, M.D. Barnes, J. Alsop, M.A. Taracila, C.R. Bethel, S.A. Becka, D. van Duin, B.N. Kreiswirth, K.S. Kaye and R.A. Bonomo. Antimicrob. Agents Chemother., 62, e00174-18 (2018); https://doi.org/10.1128/AAC.00174-18
  10. M.D. Barnes, C.R. Bethel, J. Alsop, S.A. Becka, J.D. Rutter, K.M. Papp-Wallace and R.A. Bonomo. Antimicrob. Agents Chemother., 62, e02406-17 (2018); https://doi.org/10.1128/AAC.02406-17
  11. G.G. Zhanel, C.K. Lawrence, H. Adam, F. Schweizer, S. Zelenitsky, M. Zhanel, P.R.S. Lagace-Wiens, A. Walkty, A. Denisuik, A. Golden, A.S. Gin, D.J. Hoban, J.P. Lynch III and J.A. Karlowsky, Drugs, 78, 65 (2018); https://doi.org/10.1007/s40265-017-0851-9
  12. D. Wong and D. van Duin, Drugs, 77, 615 (2017); https://doi.org/10.1007/s40265-017-0725-1
  13. R.L. Crass and M.P. Pai, Pharmacotherapy, 39, 182 (2019); https://doi.org/10.1002/phar.2210
  14. FDA Approves antibiotic to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. US Food and Drug Administration, Accessed on December 2020. Available at: FDA Approves Antibiotic to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia | FDA.
  15. S. Kohno, H. Bando, F. Yoneyama, H. Kikukawa, K. Kawahara, M. Shirakawa, N. Aoyama, M. Brown, A. Paschke and A. Takase, J. Infect. Chemother., 27, 262 (2020); https://doi.org/10.1016/j.jiac.2020.09.032
  16. J.R. Smith, J.M. Rybak and K.C. Claeys, Pharmacotherapy, 40, 343 (2020); https://doi.org/10.1002/phar.2378
  17. M.W. McCarthy, Clin. Pharmacokinet., 59, 567 (2020); https://doi.org/10.1007/s40262-020-00865-3
  18. ICH Expert Working Group, International Conference on Harmonization (ICH) of Technical Requirements for the Registration Of Pharmaceutical for Human Use Stability Testing of New Drugs Substance and Products Q1A (R2) (2003).
  19. ICH Expert Working Group. Validation of Analytical Procedures: Text and Methodology Q2 (R1) (2005).
Read More
Author biographies is not available.
Download
PDF
Statistic
Read Counter : 0 Download : 0